深度|生物医药资产大爆发后,中国创新药能走出“下一个药王”吗

第一财经
Aug 17

中国的创新药资产已日益获得全球业界的认可,并在全球创新药授权出海交易中占据了更大的“钱包份额”。然而,目前在全球市场获批的中国创新药占比仍然很低,并且中国制药和生物科技上市公司的市值整体规模远低于美国同行。根据投行高盛最近发布的一份研究报告,今年上半年,中国A/H股上市创新药公司股价年初至今已上涨78%,大幅跑赢医疗保健板块、中国股票和美国创新药同业,并且较三年下行周期谷底水平已反弹182%;年初...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10